Tranzactioneaza Bristol-Myers Squibb Company (US.BMY) - 49.19 USD (%) Tranzactioneaza
Stiri
Bristol-Myers Squibb, una dintre cele mai mari companii farmaceutice din lume, a anuntat achizitia producatorului de medicamente oncologice, Mirati Therapeutics. In acest sens, Bristol-Myers a acceptat sa plateasca 4.8 mld. USD pentru aceasta achizitie, adica 58 USD/actiune, ceea ce semnifica o prima de 52% fata de valoarea medie ponderata a pretului din ultimele 30 de zile de tranzactionare. (Sursa: news)
Bristol Myers Squibb Co (US.BMY) claims that AstraZeneca (US.AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. The lawsuit in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo. 
From the complaint: AstraZeneca exploits Plaintiffs' inventions and infringes Plaintiffs' intellectual property rights by marketing a later-developed anti-PD-L1 antibody product, Imfinzi (durvalumab), used in methods for treating cancer and for enhancing the immune response.